BCL2L1 and prostate carcinoma: Other proteins with anti-apoptotic functions, such as Mcl-1 and Bcl-xl, are known to contribute to therapy resistance in prostate cancer.45, 46, 47, 48 Robust evaluation of the apoptosis pathways to predict therapy outcome is likely to require assessment of multiple pro- and anti-apoptotic proteins in combination.49